Bone Marrow Stem Cell Neurogenesis via G-CSF Systemic Administration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating progressive neurodegenerative disorders (PNDs) like Alzheimer's and Parkinson's are invasive and risky, requiring the transplantation of in vitro-differentiated human embryonic stem cell-derived neurons, which is controversial and poses significant health risks.
Innovation Solution
Administering granulocyte-colony stimulating factor (G-CSF) in combination with autologous or donor-derived bone marrow stem cells to promote neurogenesis, facilitating the migration and differentiation of stem cells into neuron cells within the brain, thereby treating PNDs in a non-invasive manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If in vitro-differentiated human embryonic stem cell-derived neurons are transplanted, then neuronal replacement is achieved, but the treatment becomes invasive and risky requiring highly invasive intracerebral injection
Solution Approach 1:
The patent uses bone marrow as an intermediary tissue site for stem cell transplantation. Instead of directly injecting differentiated neurons into the brain (invasive), the patent transplants undifferentiated bone marrow stem cells systemically, which then migrate to the brain and differentiate into neurons in situ. This intermediary approach eliminates the need for invasive intracerebral injection while achieving the same therapeutic goal of neuronal replacement.
Solution Approach 2:
The patent inverts the conventional approach by reversing the order of differentiation and transplantation. Instead of differentiating stem cells in vitro before transplantation (conventional method), the patent transplants undifferentiated or minimally differentiated bone marrow stem cells systemically, allowing them to differentiate into neurons after reaching the brain. This inversion transforms a complex, invasive procedure into a simpler, non-invasive systemic administration.
2Reliability
If human embryonic stem cells are used for neuronal replacement, then adequate quality neurons can be obtained, but controversy over embryonic origin and availability hamper clinical applications
Solution Approach 1:
The patent employs bone marrow stem cells, which are a universal cell source available from all patients regardless of age or condition. Unlike human embryonic stem cells which face ethical controversies and availability issues, bone marrow stem cells can be obtained from autologous (patient's own) or allogeneic (donor) sources, making the therapy universally applicable to all patients with progressive neurodegenerative disorders without ethical or availability constraints.
Solution Approach 2:
The patent utilizes autologous bone marrow stem cells that can be harvested from the patient's own bone marrow, eliminating the need for embryonic tissue and associated ethical controversies. The patient's own stem cells are transplanted back into the patient, creating a self-service system that avoids interventional ethics issues while maintaining immunocompatibility and clinical applicability.
3Ease of operation
If bone marrow stem cells are transplanted systemically, then non-invasive treatment is achieved, but neurogenesis promotion requires additional G-CSF administration
Solution Approach 1:
The patent combines two therapeutic actions into a unified treatment protocol: bone marrow stem cell transplantation and G-CSF administration. The G-CSF serves multiple functions simultaneously - it promotes the migration of transplanted stem cells to the brain, enhances neurogenesis, and can be administered systemically alongside the stem cells. This merging of functions simplifies the overall treatment approach while maintaining effectiveness.
Solution Approach 2:
The patent utilizes G-CSF to change the biological parameters of the transplanted stem cells, specifically enhancing their migratory capacity and neurogenic potential. By administering G-CSF, the patent modifies the behavior and differentiation propensity of the stem cells, transforming them into an more effective therapeutic agent without requiring changes to the transplantation procedure itself.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of bone marrow stem cell transplantation and G-CSF administration stimulates neurogenesis, improving cognitive and motor functions in PND patients by increasing neuron cell proliferation and migration to the brain, effectively addressing the neuronal loss associated with these disorders.
Implementation Method 1
G-CSF promotes migration to the brain of bone marrow stem cells transplanted into a subject
Implementation Method 2
once in the brain, the stem cells differentiated into neuron cells, resulting in neurogenesis
Data Source
AI summary
A method for treating a progressive neurodegenerative disorder with bone marrow stem cells and a G-CSF receptor agonist.